Developer docs
API playgroundTry for free, no card

Search company profiles

Diaceutics

Full company profile

uuid0004llc

Namestring
Diaceutics
Legal namestring
Diaceutics PLC
Websiteurl
diaceutics.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Diaceutics PLC is a UK-headquartered precision medicine commercialization company, listed on AIM under ticker DXRX, that operates the DXRX diagnostic network platform to connect pharmaceutical companies, laboratories, and treating physicians across the therapy-launch lifecycle. The company works with the top 20 global pharmaceutical companies and a growing cohort of emerging biotechs, and reports involvement on every precision medicine brought to market over its 20+ year history, with therapeutic coverage spanning oncology, rare disease, cardiology, neurology, and autoimmune conditions. The company's stated purpose is closing the gap between diagnostic testing and appropriate therapy selection, addressing documented clinical practice gaps including 64.4% of lung cancer patients not receiving the right treatment per its 2022 JCO Precision Oncology study.

The DXRX platform integrates real-world diagnostic data from a network of 2,500+ laboratories across 51+ countries, encompassing 560 million+ de-identified patient records tokenized through Datavant and result-level data on over 24 million patients, combining lab, genomic, clinical, claims, and social determinants of health inputs. AI and machine learning power a portfolio of products: DXRX Signal (alerts within 24 hours of testing events), physician and lab segmentation modules, a disease testing rate tracker, the Physician Engage activation layer, the Expert Exchange peer-education platform, the 6A Strategic Landscape advisory framework, Targeted Commercialization engagements, and the Diagnostic Audiences product launched with Experian. The underlying stack runs on AWS, Snowflake, and Databricks with Auth0, SendGrid, and Salesforce supporting platform and CRM functions.

Diaceutics generates revenue primarily through multi-year enterprise-wide subscription engagements where customers deploy DXRX across three or more precision medicines in their portfolios, with four such FY2023 deals valued at US$20.1m in aggregate and over 50% of revenue now recurring. FY2025 reported revenue of £38.4m (20% growth), ARR of £20m (19% growth), order book of £38.9m (56% growth), and adjusted EBITDA of £7.6m (80% growth), with a return to £300k profit before tax versus a £1.9m loss in 2024. The company employs approximately 210 people across Belfast (HQ, lease extended to 2036), New York (opened January 2025), Singapore, Seoul, and Ireland.

Short descriptiontext

Diaceutics operates the DXRX diagnostic network platform, helping top 20 global pharmaceutical companies and emerging biotechs commercialize precision medicines by linking 2,500+ labs across 51 countries, AI-powered multi-modal patient data, and physician engagement workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBelfast, United Kingdom
HQ citystring
Belfast
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision medicine diagnostics, diagnostic commercialization platform, pharma data analytics, physician engagement solutions, real-world diagnostic data
Industry1 code
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Precision Medicine Data & Commercialization Platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Enterprise Software Licenses and Platform Subscriptions
TypeSubscription Recurring
Description

Multi-year enterprise-wide engagements with pharmaceutical companies deploying DXRX platform across multiple precision medicines in their portfolio. Characterized by enterprise-wide engagements typically valued at US$20.1 million for four engagements secured in FY 2023.

insidermedia.com
2Annual Recurring Revenue from Platform Services
TypeSubscription Recurring
Description

ARR of £20m representing 19% growth, driven by increasing platform adoption by large pharma customers. Revenue is approximately 50% recurring in nature.

insidermedia.com
3Data Services and Analytics
TypeSubscription Recurring
Description

Diagnostic Audiences product integrated into Experian's media-buying workflows for life sciences marketers, enabling campaign activation based on real-time diagnostic signals

trendhunter.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Enterprise-wide platform deployments
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Multi-year enterprise-wide engagements characterized by customers deploying DXRX platform across three or more precision medicines in their portfolio

insidermedia.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 8 records shown
1DXRX
Description

The world's first diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of laboratories.

diaceutics.com
+7 more records
Core offering1 text field

Diaceutics provides the DXRX diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of 2,500+ laboratories across 50+ countries with AI-powered multi-modal insights (lab, genomic, clinical, claims, SDOH). The platform enables pharmaceutical and biotech companies to identify eligible patients, segment physicians and labs, deliver real-time alerts within 24 hours of testing events, and engage healthcare providers during treatment-decision windows. Adjacent advisory and HCP engagement services (6A Strategic Landscape, Targeted Commercialization, Expert Exchange, Physician Engage) wrap the platform to deliver end-to-end therapy commercialization support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • DXRX Signal delivers actionable alerts within 24 hours of testing behaviour, enabling engagement during treatment decisions
+3 more records
Product overview1 text field

Diaceutics offers a unified platform-plus-modules architecture centered on DXRX, the world's first diagnostic commercialization platform for precision medicine. The core DXRX platform integrates real-world diagnostic data from a global network of laboratories across 50+ countries, providing the foundational data infrastructure. Three product categories extend from this platform: DXRX Data Solutions (DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, DXRX Disease Testing Rate Tracker) for intelligence and analytics; Advisory Solutions (6A Strategic Landscape, Targeted Commercialization) for strategic consulting; and HCP Engagement Solutions (DXRX Physician Engage, Expert Exchange) for physician activation. Additionally, the Diagnostic Audiences product integrates with Experian for marketing workflow automation. Together, these products enable pharma and biotech companies to identify eligible patients, improve diagnostic pathways, and engage healthcare providers at the moments that matter most.

Product and service5 records
1DXRX - The Diagnostic Network
CategoryDiagnostic Commercialization Platform
Description

The world's first diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of 2,500+ laboratories across 50+ countries. Built for pharmaceutical and biotech companies to support therapy launches and commercialization.

26A Strategic Landscape
CategoryAdvisory Solution
Description

Strategic advisory framework for mapping the precision medicine landscape and identifying commercialization opportunities, offered to pharma and biotech clients.

3Targeted Commercialization
CategoryAdvisory Solution
Description

Integrated, precision-first commercialization service uniting real-time patient insights, lab and physician behavior intelligence, and digital/expert engagement tools to help pharma teams understand markets, fix testing challenges, and reach eligible patients.

4Expert Exchange
CategoryHCP Engagement Solution
Description

Peer-to-peer education service connecting diagnostic experts with treating physicians to drive confident prescribing through trusted clinical voices explaining the test-therapeutic link in a credible, non-promotional format.

5Diagnostic Audiences
CategoryMarketing Activation Product
Description

Clinician-targeting product integrated into Experian's media-buying workflows for life sciences marketers, enabling campaign activation based on real-time diagnostic signals and biomarker results with deterministic, NPI-level precision targeting.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-27
Description

Diaceutics and Experian partnered to integrate real-time AI-driven diagnostic data into pharmaceutical marketing workflows. The collaboration embeds Diaceutics' Diagnostic Audiences into Experian's marketing platform, enabling deterministic, NPI-level precision targeting based on observed clinical events rather than retrospective prescription or claims data. The data refreshes daily, creating a near real-time feedback loop for campaign optimization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-14
Description

Strategic alliance to bring together Diaceutics' leading technology solutions and KPMG's market-leading advisory business for jointly marketing commercialisation solutions to life science customers launching precision medicines. Combines Diaceutics' data expertise with KPMG's global customer base and experience across precision medicine commercialisation and deal making.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on Clinical Practice Gaps study published in JCO Precision Oncology, working with broad stakeholder group across the Personalized Medicine Coalition to identify barriers preventing patients from receiving specialized treatments.

Strategic tierCoreTypeTechnology or Integration
Description

Data partnership enabling tokenization of over 560 million de-identified patients through Datavant's infrastructure for privacy-preserving data collaboration.

5AWS
Strategic tierCoreTypeTechnology or Integration
Description

Cloud service provider where the DXRX SaaS platform is hosted, based in Ireland.

diaceutics.com
Strategic tierCoreTypeTechnology or Integration
Description

SaaS-based data warehouse for the DXRX SaaS platform, enabling large-scale data processing and analytics.

Strategic tierSupportTypeTechnology or Integration
Description

Customer CRM used for managing customer relationships and marketing campaigns.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers1 record
TypeBroad incumbent
Description

The largest real-world data and pharma commercial analytics provider globally. Overlaps with Diaceutics on real-world diagnostic data and pharma commercialization analytics, but offers a much broader portfolio spanning clinical, commercial, and technology services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration9 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diaceutics

Precision Medicine Data & Commercialization Platformdiaceutics.com

Diaceutics operates the DXRX diagnostic network platform, helping top 20 global pharmaceutical companies and emerging biotechs commercialize precision medicines by linking 2,500+ labs across 51 countries, AI-powered multi-modal patient data, and physician engagement workflows.

What Diaceutics does

Diaceutics PLC is a UK-headquartered precision medicine commercialization company, listed on AIM under ticker DXRX, that operates the DXRX diagnostic network platform to connect pharmaceutical companies, laboratories, and treating physicians across the therapy-launch lifecycle. The company works with the top 20 global pharmaceutical companies and a growing cohort of emerging biotechs, and reports involvement on every precision medicine brought to market over its 20+ year history, with therapeutic coverage spanning oncology, rare disease, cardiology, neurology, and autoimmune conditions. The company's stated purpose is closing the gap between diagnostic testing and appropriate therapy selection, addressing documented clinical practice gaps including 64.4% of lung cancer patients not receiving the right treatment per its 2022 JCO Precision Oncology study.

The DXRX platform integrates real-world diagnostic data from a network of 2,500+ laboratories across 51+ countries, encompassing 560 million+ de-identified patient records tokenized through Datavant and result-level data on over 24 million patients, combining lab, genomic, clinical, claims, and social determinants of health inputs. AI and machine learning power a portfolio of products: DXRX Signal (alerts within 24 hours of testing events), physician and lab segmentation modules, a disease testing rate tracker, the Physician Engage activation layer, the Expert Exchange peer-education platform, the 6A Strategic Landscape advisory framework, Targeted Commercialization engagements, and the Diagnostic Audiences product launched with Experian. The underlying stack runs on AWS, Snowflake, and Databricks with Auth0, SendGrid, and Salesforce supporting platform and CRM functions.

Diaceutics generates revenue primarily through multi-year enterprise-wide subscription engagements where customers deploy DXRX across three or more precision medicines in their portfolios, with four such FY2023 deals valued at US$20.1m in aggregate and over 50% of revenue now recurring. FY2025 reported revenue of £38.4m (20% growth), ARR of £20m (19% growth), order book of £38.9m (56% growth), and adjusted EBITDA of £7.6m (80% growth), with a return to £300k profit before tax versus a £1.9m loss in 2024. The company employs approximately 210 people across Belfast (HQ, lease extended to 2036), New York (opened January 2025), Singapore, Seoul, and Ireland.

Diaceutics firmographics

Firmographics
Name
Diaceutics
Legal name
Diaceutics PLC
Website
https://diaceutics.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Diaceutics operates the DXRX diagnostic network platform, helping top 20 global pharmaceutical companies and emerging biotechs commercialize precision medicines by linking 2,500+ labs across 51 countries, AI-powered multi-modal patient data, and physician engagement workflows.
Ownership category
akta.pro rank

Diaceutics industry classification

Industry
Product category
Precision Medicine Data & Commercialization Platform
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Precision medicine diagnostics
  • Diagnostic commercialization platform
  • Pharma data analytics
  • Physician engagement solutions
  • Real-world diagnostic data

Where Diaceutics is headquartered

Location

Headquarters

HQ city
Belfast
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Diaceutics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Enterprise Software Licenses and Platform Subscriptions: Multi-year enterprise-wide engagements with pharmaceutical companies deploying DXRX platform across multiple precision medicines in their portfolio. Characterized by enterprise-wide engagements typically valued at US$20.1 million for four engagements secured in FY 2023.
  2. Annual Recurring Revenue from Platform Services: ARR of £20m representing 19% growth, driven by increasing platform adoption by large pharma customers. Revenue is approximately 50% recurring in nature.
  3. Data Services and Analytics: Diagnostic Audiences product integrated into Experian's media-buying workflows for life sciences marketers, enabling campaign activation based on real-time diagnostic signals

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise-wide platform deployments

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Diaceutics product offering

Product offering

Core offering

Diaceutics provides the DXRX diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of 2,500+ laboratories across 50+ countries with AI-powered multi-modal insights (lab, genomic, clinical, claims, SDOH). The platform enables pharmaceutical and biotech companies to identify eligible patients, segment physicians and labs, deliver real-time alerts within 24 hours of testing events, and engage healthcare providers during treatment-decision windows. Adjacent advisory and HCP engagement services (6A Strategic Landscape, Targeted Commercialization, Expert Exchange, Physician Engage) wrap the platform to deliver end-to-end therapy commercialization support.

Product overview

Diaceutics offers a unified platform-plus-modules architecture centered on DXRX, the world's first diagnostic commercialization platform for precision medicine. The core DXRX platform integrates real-world diagnostic data from a global network of laboratories across 50+ countries, providing the foundational data infrastructure. Three product categories extend from this platform: DXRX Data Solutions (DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, DXRX Disease Testing Rate Tracker) for intelligence and analytics; Advisory Solutions (6A Strategic Landscape, Targeted Commercialization) for strategic consulting; and HCP Engagement Solutions (DXRX Physician Engage, Expert Exchange) for physician activation. Additionally, the Diagnostic Audiences product integrates with Experian for marketing workflow automation. Together, these products enable pharma and biotech companies to identify eligible patients, improve diagnostic pathways, and engage healthcare providers at the moments that matter most.

Differentiator

Problem solved

Functional benefit

Brands

  • DXRX: The world's first diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of laboratories.
  • DXRX Signal
  • DXRX Physician Segmentation
  • DXRX Lab Segmentation
  • DXRX Disease Testing Rate Tracker
  • Physician Engage
  • Expert Exchange
  • PMx

Products and services

  • DXRX - The Diagnostic Network The world's first diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of 2,500+ laboratories across 50+ countries. Built for pharmaceutical and biotech companies to support therapy launches and commercialization.
  • 6A Strategic Landscape Strategic advisory framework for mapping the precision medicine landscape and identifying commercialization opportunities, offered to pharma and biotech clients.
  • Targeted Commercialization Integrated, precision-first commercialization service uniting real-time patient insights, lab and physician behavior intelligence, and digital/expert engagement tools to help pharma teams understand markets, fix testing challenges, and reach eligible patients.
  • Expert Exchange Peer-to-peer education service connecting diagnostic experts with treating physicians to drive confident prescribing through trusted clinical voices explaining the test-therapeutic link in a credible, non-promotional format.
  • Diagnostic Audiences Clinician-targeting product integrated into Experian's media-buying workflows for life sciences marketers, enabling campaign activation based on real-time diagnostic signals and biomarker results with deterministic, NPI-level precision targeting.

Quantifiable outcome

  • DXRX Signal delivers actionable alerts within 24 hours of testing behaviour, enabling engagement during treatment decisions
  • +3 more outcomes

Companies that use Diaceutics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Diaceutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability7 records

Feature6 records

Diaceutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and support.

  • ExperiancoreTechnology or Integration · 27 April 2026Diaceutics and Experian partnered to integrate real-time AI-driven diagnostic data into pharmaceutical marketing workflows. The collaboration embeds Diaceutics' Diagnostic Audiences into Experian's marketing platform, enabling deterministic, NPI-level precision targeting based on observed clinical events rather than retrospective prescription or claims data. The data refreshes daily, creating a near real-time feedback loop for campaign optimization.
  • KPMGcoreStrategic or Co-development Partner · 14 February 2024Strategic alliance to bring together Diaceutics' leading technology solutions and KPMG's market-leading advisory business for jointly marketing commercialisation solutions to life science customers launching precision medicines. Combines Diaceutics' data expertise with KPMG's global customer base and experience across precision medicine commercialisation and deal making.
  • Personalized Medicine CoalitioncoreStrategic or Co-development PartnerCollaboration on Clinical Practice Gaps study published in JCO Precision Oncology, working with broad stakeholder group across the Personalized Medicine Coalition to identify barriers preventing patients from receiving specialized treatments.
  • DatavantcoreTechnology or IntegrationData partnership enabling tokenization of over 560 million de-identified patients through Datavant's infrastructure for privacy-preserving data collaboration.
  • AWScoreTechnology or IntegrationCloud service provider where the DXRX SaaS platform is hosted, based in Ireland.
  • SnowflakecoreTechnology or IntegrationSaaS-based data warehouse for the DXRX SaaS platform, enabling large-scale data processing and analytics.
  • SalesforcesupportTechnology or IntegrationCustomer CRM used for managing customer relationships and marketing campaigns.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Diaceutics competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: The largest real-world data and pharma commercial analytics provider globally. Overlaps with Diaceutics on real-world diagnostic data and pharma commercialization analytics, but offers a much broader portfolio spanning clinical, commercial, and technology services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Diaceutics social profiles

Digital presence

Diaceutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diaceutics leadership team

Management profile

Number of profiles

Profiles11 records

Diaceutics subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Diaceutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diaceutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diaceutics

What does Diaceutics do?

Diaceutics provides the DXRX diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of 2,500+ laboratories across 50+ countries with AI-powered multi-modal insights (lab, genomic, clinical, claims, SDOH). The platform enables pharmaceutical and biotech companies to identify eligible patients, segment physicians and labs, deliver real-time alerts within 24 hours of testing events, and engage healthcare providers during treatment-decision windows. Adjacent advisory and HCP engagement services (6A Strategic Landscape, Targeted Commercialization, Expert Exchange, Physician Engage) wrap the platform to deliver end-to-end therapy commercialization support.

Is Diaceutics a public or private company?

Diaceutics is a public company. It is classified as public and is currently operating.

When was Diaceutics founded?

Diaceutics was founded in 2005. It employs 101 to 250 people.

Where is Diaceutics based?

Diaceutics is headquartered in Belfast, United Kingdom, in the Europe region.

How does Diaceutics make money?

Three revenue lines are on record. Enterprise Software Licenses and Platform Subscriptions are the primary driver. The others are annual Recurring Revenue from Platform Services and data Services and Analytics.

Who are Diaceutics's main competitors?

IQVIA is listed as a broad incumbent.

Does Diaceutics have an API?

No public API is recorded for Diaceutics.

What industry is Diaceutics in?

Diaceutics's product category is Precision Medicine Data & Commercialization Platform. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsCanaccord Genuity Group Reaffirms Buy Rating for Diaceutics (LON:DXRX)Canaccord Genuity reaffirmed a buy rating on Diaceutics with a GBX 215 target, implying 16.85% upside from the previous close. The company reported GBX 3.27 EPS for the quarter, with analysts expecting 1.01 EPS for the fiscal year.TradingViewDXRX: ARR growth and broader market reach are strengthening recurring revenue and scaleDiaceutics Plc reported H1 2026 revenue growth of 20% and ARR of GBP 29.4m, with a 149% net revenue retention rate and 6% gross ARR churn. The growth is underpinned by Precision for All and Relay expansion, pricing opportunities, and AI-led efficiency.InvestegatePrecision for All - Capital Markets WebinarDiaceutics PLC will host a virtual Capital Markets Event on 5 November 2026 to discuss its 'Precision for All' strategy. The webinar will feature senior management presentations on market opportunity and strategic positioning, with no new material trading information disclosed.BioPharma DivePrecision for All: Closing the gap between innovation and impactDiaceutics promotes a commercialization model to close gaps where eligible patients miss diagnostic-driven therapies, citing that 64% of eligible patients in advanced non-small cell lung cancer do not receive appropriate targeted therapy. The company reports a 35% uplift in new therapy starts and a 70% ROI from a rare disease program. It aims to make precision the standard for all therapies.Markets DailyDiaceutics’ (DXRX) Buy Rating Reiterated at Canaccord Genuity GroupCanaccord Genuity reiterated a buy rating on Diaceutics, setting a GBX 215 price objective. The company reported GBX 3.27 per share for the quarter, with a market cap of £163.78 million. Analysts forecast GBX 1.0107919 EPS for the current year.Markets DailyDiaceutics (LON:DXRX) Announces Quarterly Earnings ResultsDiaceutics reported quarterly earnings of GBX 3.27 per share, with a net margin of 0.25% and return on equity of 0.25%. The stock opened at GBX 181.71, and Canaccord Genuity reaffirmed a buy rating with a GBX 215 target. The consensus rating remains Buy with a GBX 215 price target.Defense WorldDiaceutics (LON:DXRX) Receives “Buy” Rating from Canaccord Genuity GroupCanaccord Genuity Group reaffirmed a buy rating on Diaceutics, setting a GBX 215 price target. The stock opened at GBX 180.50, implying a 19.11% upside. The company provides commercialization services for precision medicines.News-MedicalDiaceutics launches Precision for All Strategic Collaboration at Fierce Pharma Week 2026Diaceutics launched the Precision for All Strategic Collaboration at Fierce Pharma Week 2026, starting with an executive roundtable on diagnostic-driven therapies. Research cited shows 64% of eligible aNSCLC patients miss appropriate targeted therapy, and Diaceutics supports about 700 such therapies.InvestegateNotice of Results & PresentationsDiaceutics PLC will announce its unaudited half-year results for the period ended 30 June 2026 on 22 September 2026. An analyst webinar will be held at 1400 BST on that date. The company works with 21 of the top 30 pharma companies.FiercePharmaClosing the gap between innovation and impactA podcast episode features Diaceutics executives discussing gaps between diagnostic testing and patient access to targeted therapies. Their Practice Gaps research found patients are lost at multiple points in the care pathway, from testing to treatment selection. They explore how real-time diagnostic intelligence and improved workflows could help ensure more patients receive the right therapy.